RACURA ONCOLOGY ORDINARY (RAC) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
KalkineRacura Oncology Announces Auckland Investor Briefing and Presentation at 20th Bioshares Biotech Summit in August 2026
Racura Oncology Limited (ASX: RAC), a biopharmaceutical company in Phase 3 clinical development focused on cancer silencing therapies, has scheduled two key investor events in New Zealand for August 2026. Executive Chair Dr Peter Smith will lead a morning tea briefing for current and prospective shareholders in Auckland on 5 August 2026, followed by a presentation at the 20th Bioshares Biotech Summit in Queenstown on 7 August 2026. These occasions will provide important updates on Racura's lead ...
Bellberry Ethics Approval Activates New HARNESS Trial Sites
other announcement
Small CapsRacura Treats First Patient in HARNESS-1 Lung Cancer Trial
other announcement
Google NewsRace Oncology (ASX:RAC): Oncology Stock Commands Huge Market Interest After $34.3m Raising - Kalkine
Race Oncology (ASX:RAC): Oncology Stock Commands Huge Market Interest After $34.3m Raising Kalkine
Clinical-stage biotech Racura Oncology raises $34.3m to fully fund three cancer drug trials
Clinical-stage biotechnology company Racura Oncology (ASX: RAC) has raised a total of $34.3 million over two years to fully fund three clinical trials of its lead oncology asset RC220, completing the capital raise without paying any broker or underwriter fees. The funds, accumulated since June 2024 through a combination of bonus and "piggyb...
Racura Oncology Investor Briefings Perth & Auckland
other announcement
Racura raised $34.3m to Advance Three Oncology Trials
other announcement
Kalkine ASX Spotlight: What Weighed on Race Oncology (ASX:RAC) Shares Today? - Kalkine
Kalkine ASX Spotlight: What Weighed on Race Oncology (ASX:RAC) Shares Today? Kalkine
Racura Enters Underwriting Agreement for Options
other announcement
Racura Oncology (ASX:RAC) Surges 8% as RC220 Trial Cleared to Double Dosage Level - Stocks Down Under
Racura Oncology (ASX:RAC) Surges 8% as RC220 Trial Cleared to Double Dosage Level Stocks Down Under
CPACS Trial Cleared to Escalate to Next RC220 Dose Level
other announcement
March 2026 Quarterly Activity Report and Appendix 4C
other announcement
Racura and Wollongong Uni Granted NSW TechVoucher
other announcement
Motley FoolInsurance Australia Group's RAC Insurance deal faces ACCC Phase 2 review
Insurance Australia Group’s bid for RAC Insurance faces ACCC’s Phase 2 review over competition in Western Australia. The post Insurance Australia Group's RAC Insurance deal faces ACCC Phase 2 review appeared first on The Motley Fool Australia.
Is RACura Oncology Limited (ASX:RAC) Building Strength in All Ordinaries Biotech Sector?
Highlights RACura Oncology progresses quotation of newly issued shares on ASX. Developments align with healthcare and biotechnology sector activity. Australian indices reflect participation from medical research companies. RACura Oncology progresses share quotation, highlighting developments within the healthcare and biotechnology sector across the All Ordinaries index. The healthcare and biotechnology sector represents a vital component of Australia’s economic and innovation land...
Racura Singapore and HK Investor Briefing Update
other announcement
StockheadLong Shortz with Racura: Tackling MYC-driven cancer pathways
Racura Oncology advances its HARNESS-1 lung cancer trial, now actively recruiting, with early readouts expected later this year. ... Read More The post Long Shortz with Racura: Tackling MYC-driven cancer pathways appeared first on Stockhead.
First Patient Recruited to HARNESS-1 Lung Cancer Trial
other announcement
Racura and Purdue University Partnership Announced
other announcement